Compare Charles River Laboratories Intl. Inc (CRL) vs KraneShares CSI China Internet ETF (KWEB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs KraneShares CSI China Internet ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $232.3 (market cap $11.14B), while KraneShares CSI China Internet ETF trades at $26.67. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, KraneShares CSI China Internet ETF nearer its low. Which is the better fit depends on your goals.
| CRL | KWEB | |
|---|---|---|
Market Cap | $11.14B | — |
Sector | Health | Sector/Thematic |
52-Week High | $233.60 | $42.94 |
52-Week Low | $145.57 | $23.63 |
Enterprise Value | $14.00B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
KWEB trades at $26.23, down 0.57% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF provides exposure to Chinese internet and AI companies, benefiting from government support and AI-driven growth, though key financial ratios are unavailable. Recent news highlights China's push for tech self-reliance and strong export performance.
Outlook is mixed: AI expansion and attractive valuations offer upside, but geopolitical tensions and regulatory risks pose challenges. The stock's performance hinges on China's economic policies and global tech competition, requiring careful risk assessment for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About KraneShares CSI China Internet ETF
KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →
